This is a news story, published by Yahoo, that relates primarily to Novo Nordisk news.
For more Novo Nordisk news, you can click here:
more Novo Nordisk newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
weight loss drugs Ozempic. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest weight loss drug news, Alzheimer news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
diabetes drugNBC News
•84% Informative
A weight loss drug similar to Ozempic appeared to slow cognitive decline in patients with mild Alzheimer’s disease.
The findings add to the growing evidence that GLP-1 agonists may also protect the brain.
Novo Nordisk is running two phase 3 clinical trials that will compare semaglutide to a placebo.
The existing Alzheimer’s drugs, Leqembi and Kisunla , target only one component of the disease: amyloid plaque.
The GLP-1 drugs, however, could work in “nonspecific” ways, experts say.
VR Score
85
Informative language
85
Neutral language
43
Article tone
semi-formal
Language
English
Language complexity
52
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
16
Source diversity
5
Affiliate links
no affiliate links